Pyxis Oncology is trading 5.6% up at $3.37, supported by its 9:30 a.m. H.C. Wainwright conference presentation and recent analyst optimism on September 14, 2026.
- H.C. Wainwright raised its price target to $8 from $7 while maintaining a Buy rating.
- The company’s investor-relations calendar confirms the conference event.
- Pyxis Oncology is outperforming a broadly weaker market, though the immediate catalyst remains uncertain.